Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases

Area of Science:

• Mitochondrial biology
• Metabolic diseases
• Neurodegenerative disorders

Background:

• Mitochondrial dysfunction is linked to diseases, particularly neurodegenerative conditions and type 2 diabetes.
• Impaired mitochondrial ATP production and reduced oxidative capacity are associated with insulin resistance, obesity, and diabetes.
• Factors like oxidative stress and altered mitochondrial biogenesis contribute to mitochondrial dysfunction.

Purpose of the Study:

• To review the association between mitochondrial function and diseases.
• To highlight the protective role of Insulin-like Growth Factor 1 (IGF-1) in mitochondrial health.
• To explore IGF-1 as a potential therapeutic target for mitochondrial dysfunction and associated metabolic disorders.

Main Methods:

• Literature review focusing on mitochondrial function, diseases, and IGF-1.
• Analysis of experimental models demonstrating IGF-1's effects (e.g., cirrhosis, aging).
• Examination of gene array data linking mitochondrial gene expression to insulin resistance and type 2 diabetes.

Main Results:

• IGF-1 acts as a significant mitochondrial protector across various experimental models.
• Mitochondrial dysfunction contributes to insulin resistance and type 2 diabetes mellitus.
• Low-dose IGF-1 therapy demonstrates beneficial effects, including improved insulin resistance, lipid metabolism, and organ protection.

Conclusions:

• Understanding mechanisms of mitochondrial biogenesis, metabolism, mitophagy, and apoptosis is crucial for developing therapies.
• Low-dose IGF-1 therapy is a promising strategy for mitigating mitochondrial dysfunction.
• IGF-1 treatment offers potential therapeutic benefits for conditions associated with mitochondrial dysfunction, including metabolic and neurodegenerative diseases.